

# Uri Ben-David

Department of Human Molecular Genetics & Biochemistry, Tel Aviv University

+972-54-6004444 | [ubendavid@tauex.tau.ac.il](mailto:ubendavid@tauex.tau.ac.il)

ORCID ID: 0000-0001-7098-2378

## ACADEMIC POSITIONS

- 10/2019-date      **Senior Lecturer (Assistant Professor)**, Department of Human Molecular Genetics & Biochemistry, Faculty of Medicine, Tel-Aviv University.
- 2014-2019        **Postdoctoral Fellow at the Broad Institute of Harvard and MIT**, Cambridge, MA, under the supervision of Prof. Todd R. Golub, Director of Cancer Program.

## EDUCATION

- 2010-2014        **Ph.D. studies at the Hebrew University of Jerusalem**, Israel, under the supervision of Prof. Nissim Benvenisty, Stem Cell Unit, Dept. of Genetics, Life Sciences Institute. PhD thesis title: “Genomic instability and tumorigenicity of human pluripotent stem cells”.
- 2009-2010        **M.Sc. studies, Dept. of Genetics, Life Sciences Institute, Hebrew University.**  
Average of M.Sc. studies: **98.4/100**. Direct Ph.D. program entrance exam: **99/100**.
- 2006-2009        **B.Sc. studies, *summa cum laude*, Life sciences and Cognitive sciences, Hebrew University.** Studies within the excellence program of the Exact Sciences Faculty, “Amirim Teva”. Average of B.Sc. studies: **98/100**.

## TEACHING AND TRAINING EXPERIENCE

- 2021 to date      Teaching the basic “Introduction to Molecular Biology” course for 1<sup>st</sup> year medical school students (~200 students)  
Accredited by the TAU BLEND Program for Innovation in Teaching & Learning
- 2020 to date      Teaching a graduate level course on “Scientific Writing”
- 2019 to date      Mentoring 3 Staff Scientists, 1 postdoc, 2 PhD students, 3 MD/PhD students, one MD thesis student, and 6 undergraduate students
- 2016-2018        Coaching in the Cancer Program “Bootcamp” Training
- 2016-2019        Training and mentoring a full-time Research Associate
- 2012-2019        Training and mentoring undergraduate students
- 2012-2014        Teaching assistant at the Hebrew University Life Sciences Institute:  
Human Genetics course for 3<sup>rd</sup> year biology students
- 2010-2012        Teaching assistant at the Hebrew University Life Sciences Institute:  
General Genetics course for 1<sup>st</sup> year biology students

## OTHER EXPERIENCE

- 2011-2014        Translating Latino American literature from Spanish to Hebrew:

Jorge Luis Borges' *De que nada se sabe*, Carmel Publishing House (2012)  
 Reinaldo Arenas' *Celestino antes del alba*, Carmel Publishing House (2014)  
 2011-2014 Volunteering with high school students (through "Hoshen" organization)  
 2007-2014 Volunteering with holocaust survivors (through "Amcha" organization)  
 2001-2006 Military service as an intelligence officer in a special intelligence unit, **with honors**

## LANGUAGES

Hebrew Native speaker  
 English Very high level  
 Spanish Medium level

## INDEPENDENT GRANTS & RESEARCH FUNDS

### Ongoing Active Grants

2021-2025 **Israel Precision Medicine Partnership (IPMP) Research Grant** (co-PI with Prof. Ittai Ben-Porath and Dr. Amir Sonnenblick; \$680K total)  
 2021-2026 **Israel Science Foundation Project Grant** (\$420K total)  
 2021-2024 **Israel Science Foundation New Faculty Equipment Grant** (\$240K total)  
 2021-2026 **The European Research Council (ERC) Starting Grant** (\$1.85M total)  
 2021-2023 **NovoCure Tumor Treating Fields Research Grant** (\$220K total)  
 2021-2022 **The Forbeck Foundation Accelerator Grant** (\$30K total)  
 2021-2022 **The TAU/CBRC-LaTrobe/ONJ Collaboration Grant** (co-PI with Prof. Delphine Merino; \$30K total)  
 2021-2022 **The Clinical-Bioinformatics Collaboration Grant** of the Edmond J. Safra Center for Bioinformatics and the School of Medicine at TAU (co-PI with Prof. Benny Dekel; \$20K total)  
 2021-2022 **The Faculty of Medicine Research Foundation Seed Grant** (\$11K total)  
 2021 **The Shtacher Award for Biomedical Research** (\$8K total)  
 2021 **The WGRF COVID-19 Recovery Grant** (\$15K total)  
 2020-2023 **The Israel Cancer Research Fund 'Gesher' Award** (\$176K total)  
 2020-2024 **The United States – Israel Binational Science Foundation Research Grant** (co-PI with Prof. Angelika Amon from MIT; \$224K total)  
 2020-2023 **The Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP) Career Development Award** (\$450K total)  
 2020-2021 **The Israel Cancer Association Research Grant** (\$23K total)  
 2019-2022 **The Azrieli Foundation Faculty Fellowship** (\$210K total)

### Previous Funding

2020 **The Cancer Biology Research Center Research Grant** (\$20K total)  
 2019-2020 **The Eimert Research Fund on Solid Tumors** (\$50K total)  
 2019-2022 **The National Cancer Institute (NCI) Career Transition Award (K22)** (\$450K total, relinquished)

2019-2024 **Cancer Prevention and Research Institute of Texas** Recruitment of First-Time Tenure-Track Faculty Members (\$2M total, relinquished)  
 2016-2017 The Broad Institute **Broadnext10** research grant (\$75K total)

## ACADEMIC AWARDS & SCHOLARSHIPS

### International

2022-2026 **EMBO Young Investigator Member**  
 2021 **Cells 2021 Young Investigator Award**  
 2020 The American Association for Cancer Research (AACR) '**Next Generation Star**' Award  
 2018 **Pacific Symposium on Biocomputing Research Parasite Award** for outstanding secondary analysis of data  
 2016 **AACR-Susan G. Komen Scholar-in-Training Award** for participation at the American Association for Cancer Research annual meeting (New Orleans, USA)  
 2015 **American Society of Cell Biology Kaluza Prize** for outstanding Ph.D. dissertation  
 2016-2020 **Forbeck Research Foundation Scholar Award** in the field of Aneuploidy and Chromosomal Instability  
 2015 Selected participant at the 65<sup>th</sup> **Lindau Nobel Laureate Meeting** (Lindau, Germany)  
 2015-2018 **Human Frontier Science Program Postdoc Fellowship**  
 2014-2015 **EMBO Long Term Postdoc Fellowship**  
 2013 **The Dan David Scholarship Award**, Future Time Dimension, Preventive Medicine  
 2013 **Best Poster Award**, Israel Stem Cell Society (ISCS) 5<sup>th</sup> international meeting  
 2013 **Travel Award Grant** for oral presentation, International Society for Stem Cell Research (ISSCR) 11<sup>th</sup> annual conference (Boston, USA)  
 2012 Participant at the **Merck Serono Innovation Cup 2012**  
 2012 **Travel Award Grant** for oral presentation, International Society for Stem Cell Research (ISSCR) 10<sup>th</sup> annual conference (Yokohama, Japan)  
 2011 **Travel Award Grant** for oral presentation, International Society for Stem Cell Research (ISSCR) 9<sup>th</sup> annual conference (Toronto, Canada)  
 2010 **Travel Award Grant** for poster presentation, International Society for Stem Cell Research 8<sup>th</sup> annual conference (San Francisco, USA)

### National

2022 **Krill Prize** for Excellence in Scientific Research  
 2014 **Rothschild Postdoc Fellowship**  
 2012-2014 **Clore Foundation Scholarship** for outstanding Ph.D. students  
 2011 **Aharon Katzir Student Travel Fellowship**

### Institutional

2021	<b>The Shtacher Award for Biomedical Research</b> for an excellent researcher at the Department of Human Molecular Genetics & Biochemistry
2018, 2019	<b>Best Poster Award</b> , The Annual Cancer Genetics Symposium of Dana-Farber and Harvard Cancer Center (Boston, USA)
2015	<b>The Hans Weiner Prize</b> for outstanding Ph.D. dissertation, Hebrew University
2014	<b>The Dimitris N. Chorafas Foundation Award</b> for outstanding Ph.D. dissertation
2013	<b>The Kaye Innovation Award</b> , 1 <sup>st</sup> prize for students
2013	<b>Menashe Markus Prize</b> for an outstanding Ph.D. student at the Dept. of Genetics
2010-2014	<b>Dean's List of Outstanding Teachers</b> for the years 2011, 2012, 2013 and 2014
2010-2013	<b>SMART Prize</b> for the best article of the month, Life Sciences Institute. Awarded five times: Oct 2010, Aug 2011, Feb 2012, Feb 2013 and Aug 2013
2012	<b>Best Poster Award</b> , Faculty of Natural Sciences posters contest
2012	<b>Travel Grant</b> from the Research Students Authority of the Hebrew University
2011	<b>SMART Prize</b> for best article of the year (2010), Life Sciences Institute
2010	<b>Pollack Prize</b> for excellent M.Sc. students
2009	<b>Excellence Scholarship</b> for M.Sc. students (from Hebrew University)
2008	<b>Rector's Prize</b> , second year of B.Sc. studies
2007-2009	<b>Dean's Prize</b> , first, second and third year of B.Sc. studies
2007-2009	<b>Excellence Scholarship</b> for B.Sc. students ("Amirim Teva" program)

## REVIEWING ACTIVITY & EDITORIAL BOARDS

2013 to date	Ad hoc reviewer of >60 manuscripts for <i>Nature</i> , <i>Nature Genetics</i> , <i>Nature Cancer</i> , <i>Nature Biotechnology</i> , <i>Nature Cell Biology</i> , <i>Cancer Discovery</i> , <i>Cancer Research</i> , <i>Nature Reviews Cancer</i> , <i>Nature Reviews Drug Discovery</i> , <i>Nature Reviews Molecular Cell Biology</i> , <i>Cell Systems</i> , <i>Science Advances</i> , <i>Stem Cell Reports</i> , <i>Nature Communications</i> , <i>PLoS Computational Biology</i> , <i>The EMBO Journal</i> , <i>Molecular Systems Biology</i> , <i>Nucleic Acids Research</i> , <i>npj Precision Oncology</i> , <i>Molecular Cancer Therapeutics</i> , <i>eLife</i> , <i>Review Commons</i> , <i>Stem Cells</i> , <i>Stem Cells Translational Medicine</i> , <i>PLoS One</i> , <i>Communications Biology</i> , <i>Seminars in Cell and Developmental Biology</i> , <i>Molecular and Cellular Therapies</i>
2014 to date	Ad hoc reviewer of >20 grant applications for the European Research Council (ERC) Starting Grant, Israel Science Foundation (ISF), Israel Cancer Association (ICA), Swiss Cancer Research Foundation, Austrian Science Fund (FWF), Worldwide Cancer Research (WCR), Cancer Research Trust New Zealand, Azrieli Postdoctoral Fellowship Program, Czech Science Foundation, International Society for Stem Cell Research (ISSCR)
2013-2016	Advisory Board member of <i>Molecular and Cellular Therapies</i>
2011-2019	Indirect ad hoc reviewer (through PI) of >20 manuscripts for <i>Nature</i> , <i>Cell</i> , <i>Nature Genetics</i> , <i>Nature Biotechnology</i> , <i>Cell Stem Cell</i> , <i>Stem Cell Reports</i> , <i>Stem Cells</i> , <i>Nature Communications</i> , <i>EMBO Molecular Medicine</i>

## COMMITTEES & ORGANIZATIONAL DUTIES

### International & National

2021-date	BSF Scientific Advisory Panel (regular grants program)
2021	Technion Human Health Initiative (THHI) scientific advisory committee
2020-date	Member of Ph.D thesis committees at DKFZ and at Technion (x2)
2019 to date	International member of Ph.D. thesis juries, for the Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium (x2) and for the Institute of Biomedical sciences, University of Porto, Porto, Portugal

### Institutional

2022-date	Interviewing and evaluating PhD candidates for the faculty
2021	Safra Bioinformatics Retreat Program Committee
2020-date	Member of Ph.D thesis committees (x3); M.Sc. thesis committees (x4); and an M.D. thesis committee (x1)
2020 to date	Member of the Instrumentation and Service Center Committee, Faculty of Medicine, TAU
2020 to date	Organizing the weekly Departmental Seminar Series, Department of Human Molecular Genetics & Biochemistry, Faculty of Medicine, TAU
2019 to date	Reviewing multiple (>10) internal faculty grant applications and thesis proposals

## ORAL PRESENTATIONS

### International

2023	Fondation des Treilles Meeting on DNA Damage in Mitosis, Provence, France ( <b>invited speaker</b> )
2023	Gordon Research Conference on Molecular Mechanisms of Evolution, Boston, USA ( <b>invited speaker</b> )
2022	The FASEB Meeting on Consequences of Aneuploidy, Boston, USA ( <b>invited speaker</b> )
2022	Olivia Newton-Johan Cancer Research Institute (ONJCRI) 2022 Seminar Series, Melbourne, Australia ( <b>invited speaker</b> ; online lecture)
2022	The EMBO Young Investigators Sectoral Meeting on Cancer, Benasque, Spain ( <b>invited speaker</b> )
2022	The EMBO Young Investigators Annual Meeting, Heidelberg, Germany ( <b>invited speaker</b> )
2022	EMBO Meeting on Chromosome Segregation and Aneuploidy, Vienna, Austria ( <b>invited speaker</b> )
2022	Forbeck Meeting on Aneuploidy in Cancer Development, Prognosis and Treatment, Oleggio Castello, Italy ( <b>conference co-chair and invited speaker</b> )
2022	The Annual Portuguese Genetics Meeting (“Portugaliae Genetica”), Porto, Portugal ( <b>invited keynote speaker</b> )

- 2021 The University of Minnesota Ovarian Cancer Conference, Minneapolis, USA (**invited keynote speaker**)
- 2021 The University of Virginia (UVA) Cancer Center Seminar, Charlottesville, USA (**invited speaker**, online lecture)
- 2021 The Japanese Cancer Association 80<sup>th</sup> Annual Meeting, Yokohama, Japan (**invited speaker**, online lecture)
- 2021 Harvard Medical School, Boston, USA (**invited speaker**, online lecture)
- 2021 Front Line Genomics Webinar on Cancer Genomics, (**invited speaker**, online meeting)
- 2021 Aneuploidy and Chromosomal Instability Forum, NY, USA (**invited speaker**, online meeting)
- 2021 HUGO Human Genome Meeting (**invited speaker**, online meeting)
- 2021 Regina Elena National Cancer Institute, Rome, Italy (**invited speaker**, online lecture)
- 2021 The 33<sup>rd</sup> Annual Lorne Cancer Conference, Lorne, Australia (**invited keynote speaker**, online meeting)
- 2021 ICRF Brilliant Minds Webinar Series (**invited speaker**, online lecture)
- 2020 The University of Milan, Course on Biomedical Omics for M.Sc. students, Milan, Italy (**invited speaker**; online lecture)
- 2020 The UCL Genetics Institute Seminar Series, London, UK (**invited speaker**; online lecture)
- 2020 The Adamas University, Calcutta, India (**invited speaker**; online lecture)
- 2020 The American Association for Cancer Research (AACR) annual meeting, San Diego, USA (**invited speaker**; online meeting)
- 2020 The European Association for Cancer Research (EACR) 26<sup>th</sup> congress, Torino, Italy (online meeting)
- 2020 The European Institute of Oncology (EIO), Milan, Italy (**invited speaker**; cancelled due to COVID-19)
- 2020 The Annual Portuguese Genetics Meeting (“Portugaliae Genetica”), Porto, Portugal (**invited keynote speaker**; cancelled due to COVID-19)
- 2019 The Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium (**invited speaker**)
- 2019 The Forbeck Foundation Annual Scholar Retreat, Wisconsin, USA (**invited speaker**)
- 2019 MIT Center for Precision Cancer Medicine Seminar Series, Cambridge, USA (**invited speaker**)
- 2019 Gordon Research Conference on Cell Growth and Proliferation, Vermont, USA
- 2019 EMBO Policy Workshop on Cell Line Heterogeneity, Heidelberg, Germany (**invited speaker**)
- 2019 EMBO Chromosome Segregation and Aneuploidy Workshop, Cascais, Portugal
- 2019 The Functional Genomics Consortium, Cambridge, USA (**invited speaker**)
- 2018 The Forbeck Foundation Annual Scholar Retreat, Wisconsin, USA (**invited speaker**)
- 2018 EACR-AACR-ISCR Conference: The Cutting Edge of Contemporary Cancer Research, Jerusalem, Israel

- 2018 The EurOPDX Workshop on Preclinical Models in Clinical Oncology and Cancer Precision Medicine, Weggis, Switzerland (**invited keynote speaker**)
- 2018 Cold Spring Harbor Laboratory Meeting on Mechanisms and Models of Cancer, Cold Spring Harbor, USA
- 2018 The Joint Center for Cancer Genome Discovery (CCGD)-Profile Conference, Boston, USA (**invited speaker**)
- 2018 The Human Cancer Models Initiative Meeting, Rockville, USA (**invited speaker**)
- 2017 The American Society of Cell Biology (ASCB) – European Molecular Biology Organization (EMBO) Annual Meeting, Philadelphia, USA
- 2017 The Forbeck Foundation Annual Scholar Retreat, Wisconsin, USA (**invited speaker**)
- 2017 The PSCP-ISCI Genetics Workshop, Sheffield, UK (**invited speaker**)
- 2016 The Forbeck Foundation Annual Forum, North Carolina, USA
- 2016 EMBO Fellows meeting, Boston, USA
- 2016 The International Stem Cell Initiative (ISCI) workshop, Bar Harbor, USA (**invited session co-chair**)
- 2016 IPITA-JDRF Key Opinion Leaders Meeting on Stem Cell Derived Beta Cells Boston, USA (**invited speaker**)
- 2016 EMBO Fellows meeting, Heidelberg, Germany
- 2016 The American Association for Cancer Research (AACR) annual meeting, New-Orleans, USA
- 2015 The American Society for Cell Biology (ASCB) annual meeting, San-Diego, USA (**invited speaker**)
- 2015 The 65<sup>th</sup> Lindau Nobel Laureate Meeting, Lindau, Germany
- 2014 Memorial Sloan Kettering Cancer Center, New-York, USA (**invited speaker**)
- 2014 New Questions, New Answers: NZ Bioethics Conference, Dunedin, New-Zealand
- 2013 International Society for Stem Cell Research (ISSCR) 11<sup>th</sup> annual meeting, Boston, USA
- 2012 Drug Safety of Stem Cells and other Novel Therapeutics course, Liverpool, United Kingdom (**invited speaker**)
- 2012 International Society for Stem Cell Research (ISSCR) 10<sup>th</sup> annual meeting, Yokohama, Japan
- 2011 International Society for Stem Cell Research (ISSCR) 9<sup>th</sup> annual meeting, Toronto, Canada

### National

- 2023 ILANIT/FISEB congress of the Federation of the Israeli Societies for Experimental Biology, Eilat, Israel (**invited speaker**)
- 2022 Faculty of Biology Lecture Series, Technion, Israel (**invited speaker**)
- 2022 Felsenstein Medical Research Center Seminar Series, Petah Tikva, Israel (**invited speaker**)
- 2021 Weizmann Institute Cancer Club Lecture Series, Rehovot, Israel

- (invited speaker)**
- 2021 Sourasky Medical Center Basic Science Seminar Series, Tel Aviv, Israel  
**(invited speaker)**
- 2021 Israel Society for Cancer Research (ISCR) Annual Meeting  
**(invited speaker, online meeting)**
- 2021 Department of Clinical Biochemistry & Pharmacology, Ben-Gurion University, Beer-Sheva, Israel **(invited speaker)**
- 2020 From Basic Research to Innovative Therapies, Weizmann Institute, Rehovot, Israel (cancelled due to COVID-19)
- 2020 ILANIT/FISEB congress of the Federation of the Israeli Societies for Experimental Biology, Eilat, Israel **(invited speaker)**
- 2020 World Cancer Day, Tel Aviv, Israel **(invited speaker)**
- 2019 The Annual Meeting of the Israeli Society of Gene and Cell Therapy, Tel Aviv, Israel
- 2013 Israeli Society of Gene and Cell Therapy (ISGCT) 8<sup>th</sup> annual meeting, Jerusalem, Israel (accepted)
- 2013 Sheba Cancer Research Center seminar, Ramat-Gan, Israel **(invited speaker)**
- 2012 The 1<sup>st</sup> Graduate Students' Conference in Genetics, Genomics and Evolution, Beer-Sheva, Israel (accepted)
- 2012 Israeli Society for Cancer Research (ISCR) 4<sup>th</sup> annual meeting, Ramat-Gan, Israel
- 2011 Israel Stem Cell Society (ISCS) 4<sup>th</sup> international meeting, Tel Aviv, Israel
- 2011 ILANIT/FISEB congress of the Federation of the Israeli Societies for Experimental Biology, Eilat, Israel
- 2010 Israel Stem Cell Society (ISCS) Young Investigators conference, Tel Aviv, Israel

### Institutional

- 2022 Cancer Biology Research Center (CBRC) seminar  
**(invited speaker, online meeting)**
- 2020 1<sup>st</sup> conference for collaborative research between Safra Center for Bioinformatics and TAU-affiliated hospital-based MDs, Tel Aviv, Israel  
**(invited speaker, online meeting)**
- 2020 The Annual Retreat of the TAU Safra Center for Bioinformatics, Maagan, Israel  
**(invited speaker; online meeting)**
- 2018 The 14<sup>th</sup> Annual Broad Institute Retreat, Boston, USA **(invited speaker)**
- 2018 The Broad Institute Board of Scientific Counselors Annual Meeting, Boston, USA **(invited speaker)**
- 2018 The Broad Institute Trainee Retreat, Boston, USA
- 2012 Alexander Silberman Institute for the Life Sciences (AS-ILS) annual meeting, Ma'agan, Israel



## POSTER PRESENTATIONS

- 2018 Dana-Farber/Harvard Cancer Center Cancer Genetics Symposium, Boston, USA
- 2018 The American Association for Cancer Research (AACR) annual meeting, Chicago, USA
- 2017 The 13<sup>th</sup> annual Broad Retreat, Boston, USA
- 2017 The 5<sup>th</sup> annual Broad-ISF Cell Circuits Symposium, Jerusalem, Israel
- 2017 The HFSP Fellows Meeting, Lisbon, Portugal
- 2017 The Klarman Cell Observatory Retreat, Boston, USA
- 2016 The 12<sup>th</sup> annual Broad Retreat, Boston, USA
- 2016 The 4<sup>th</sup> annual Broad-ISF Cell Circuits Symposium, Boston, USA
- 2015 Howard Hughes Medical Institute (HHMI) Science Meeting, Janelia, USA
- 2014 Israeli Society for Cancer Research (ISCR) 6<sup>th</sup> annual meeting, Haifa, Israel
- 2013 First Israel-China workshop on Genetics and Epigenetics of Human Disease, Jerusalem, Israel
- 2013 Israel Stem Cell Society (ISCS) 5<sup>th</sup> international meeting, Jerusalem, Israel
- 2013 Stem Cells and Regenerative Medicine conference, Jerusalem, Israel
- 2013 International Society for Stem Cell Research (ISSCR) 11<sup>th</sup> annual meeting, Boston, USA
- 2013 Israeli Society for Cancer Research (ISCR) 5<sup>th</sup> annual meeting, Beer-Sheva, Israel
- 2013 Gordon Research Conference on Stem Cells and Cancer, Les Diablerets, Switzerland
- 2012 Faculty of Natural Sciences Posters Contest, Jerusalem, Israel
- 2011 Israel Society for Cancer Research (ISCR) 3<sup>rd</sup> annual meeting, Jerusalem, Israel
- 2011 Molecular Medicine: Cancer Biology and Therapy conference, Jerusalem, Israel
- 2011 UK-Israel Regenerative Medicine Conference, Beer-Sheva, Israel

## PUBLICATIONS

Total number of citations: 5,726; H-index: 28 (Google Scholar, January 11, 2022)

# Corresponding author; \* Equally-contributing first-author

## ORIGINAL RESEARCH ARTICLES

### 2022

1. Hoge A.C.H.\*, Getz M.\*, Beroukhim R., Golub T.R., Ha G.# and **Ben-David U.**# DNA-based copy number analysis confirms genomic evolution of PDX models. *npj Precision Oncology*, 2022 (accepted), doi.org/10.1101/2021.01.15.426865 (bioRxiv). **IF=8.3**
2. Prasad K., Bloomfield M., Levi H., Keuper K., Bernhard S.V., Baudoin N.C., Leor G., Eliezer Y., Giam M., Wong C.K., Rancati G., Storchova Z., Cimini D., and **Ben-David U.**# Whole-genome duplication shapes the aneuploidy landscape of human cancers. *Cancer Research*, 2022, doi:10.1158/0008-5472.CAN-21-2065 (ePub ahead of print). **IF=12.7**

### 2021

3. Ippolito M., Martis V., Hong C., Wardenaar R., Zerbib J., Spierings D.C.J., **Ben-David U.**, Fojjer F., and Santaguida S. Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. *Developmental Cell*, 2021, S1534-5807(21)00562-1, doi: 10.1016/j.devcel.2021.07.006. **IF=10.1**
4. Vaz S., Ferreira F.J., Macedo J.C., Leor G., **Ben-David U.**, Bessa J., and Logarinho E. BMF repression by FoxM1 inhibits anoikis during mitosis and is a biomarker for antimetastatic chemotherapy response. *Cell Death & Disease*, 2021, 12(6):542, doi: 10.1038/s41419-021-03822-5. **IF=8.5**.
5. Wang R.W., Vigano S., **Ben-David U.**, Amon A., and Santaguida S. Aneuploid senescent cells activate NF- $\kappa$ B to promote their immune clearance by NK cells. *EMBO Reports* 2021, 22(8):e52032, doi: 10.15252/embr.202052032. **IF=8.8**.
6. Cohen-Sharir Y., McFarland J., Abdusamad M., Marquis C., Bernhard S.V., Kazachkova M., Tang H., Ippolito M.R., Laue K., Zerbib J., Malaby H.L.H., Jones H., Stautmeister L.-M., Bockaj I., Wardenaar R., Lyons N., Nagaraja A., Bass A.J., Spierings D.C.J., Fojjer F., Beroukhim R., Santaguida S., Golub T.R., Stumpff J., Storchova Z., and **Ben-David U.**# Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. *Nature* 2021, 590(7846):486-491, doi: 10.1038/s41586-020-03114-6. **IF=50.0**

# "Research Highlight" in *Cancer Discovery* (doi: 10.1158/2159-8290.CD-RW2021-017)

# "News & Views" comment in *Nature Communications* (doi: 10.1038/s41467-021-23965-5)

# A provisional patent application was submitted based on this work.

# Highlighted in news stories in the popular press (**New York Post**, **Ynet**, **GEN**, **Doctors Only**, and more)

### 2020

7. Replogle J., Zhou W., Amaro A., McFarland J., Villalobos-Ortiz M., Ryan J., Letai, A., Yilmaz O., Sheltzer J., Lippard S., **Ben-David U.**, and Amon A. Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division. *Proc Natl Acad Sci U S A*, 2020, 117(48):30566-30576, doi.org/10.1073/pnas.2009506117. **IF=11.2**.
8. Winkler T. and **Ben-David U.** # Elevated ACE2 expression levels in tumor-adjacent tissues of cancer patients. *International Journal of Cancer*, 2020, 147(11):3264-3266, doi.org/10.1002/ijc.33145. **IF=7.4**

# Selected for a special issue for the 2021 World Cancer Day

9. Enache O.M.\*, Rendo V.\*, Abdusamad M., Lam D., Davison D., Pal S., Currimjee N., Hess J., Sanson K., Pantel S., Nag A., Thorner A., Root D., Doench J.G., Vazquez F., Beroukhim R., Golub T.R., and **Ben-David U.** # Cas9 activates the p53 pathway and selects for p53-inactivating mutations. *Nature Genetics*, 2020, 52(7):662-668, doi: 10.1038/s41588-020-0623-4. **IF=38.3**

# The cover of the journal was dedicated to this article

# “Research Highlight” in *Cancer Discovery* (doi: 10.1158/2159-8290.CD-RW2020-081)

# Invited paper presentation in *JRNlclub* (<https://jrnclub.org/>)

# A provisional patent application was submitted based on this work

10. Corsello S.M., Nagari R.T., Spangler R.D., Rossen J., Kocak M., Bryan J.G., Humeidi R., Peck D., Wu X., Tang A.A., Wang V.M., Bender S.A., Lemire E., Narayan R., Montgomery P., **Ben-David U.**, Chen Y., Rees M.G., Lyons N.J., McFarland J.M., Wong B.T., Wang L., Dumont N., O’Hearn P.J., Stefan E., Doench J.G., Greulich H., Meyerson M., Vazquez F., Subramanian A., Roth J.A., Bittker J.A., Boehm J.S., Mader C.C., Tsherniak A., and Golub T.R. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. *Nature Cancer*, 2020, 1(2):235-248, doi: 10.1038/s43018-019-0018-6. **IF=NA**

## 2018

11. **Ben-David U.**, Siranosian B., Ha G., Tang H., Oren Y., Hinohara K., Strathdee c.A., Dempster J., Lyons N.J., Burns R., Nag A., Kugener G., Cimini B., Tsvetkov P., Maruvka Y.E., O’Rourke R., Garrity A., Tubelli A.A., Bandopadhyay P., Tsherniak A., Vazquez F., Wong B., Birger C., Ghandi M, Thorner A.R., Bittker J.A., Meyerson M., Getz G., Beroukhim R. and Golub T.R. Genetic and transcriptional evolution alters cancer cell line drug response. *Nature*, 2018, 560(7718):325-330, doi: 10.1038/s41586-018-0409-3. **IF=50.0**

# The cover of the journal was dedicated to this article

# Highlighted in a Broad Press Release and Video

# Highlighted in a “News and Views” article in *Disease Models & Mechanisms* (doi: 10.1242/dmm.037366)

# Highlighted in news stories in the popular press (**STAT+**, **Haaretz**, and more)

12. Abdeen S.A., **Ben-David U.**, Maly B. and Aqueilan R. Somatic loss of WWOX drives triple-negative breast cancer through perturbation of TP53. *Cell Death & Disease*, 2018, 9(8):832, doi: 10.1038/s41419-018-0896-z. **IF =8.5**

## 2017

13. **Ben-David U.**, Ha G., Tseng Y.Y., Greenwald N.F., Oh C., Shih J., McFarland J.M., Wong B., Boehm J.S., Beroukhim R. and Golub T.R. Patient-derived xenografts undergo mouse-specific tumor evolution. *Nature Genetics*, 2017, 49(11):1567-1575, doi:10.1038/ng.3967. **IF= 38.3**

# Highlighted in a “News and Views” article in *Nature Genetics* (doi:10.1038/ng.3983)

# Highlighted in two news stories in *Nature* (doi:10.1038/nature.2017.22782 and doi: 10.1038/d41586-018-05890-8)

# Highlighted in a news story in *Cancer Discovery* (doi: 10.1158/2159-8290.CD-NB2017-151)

# Highlighted in news stories in the popular press (*The Scientist*, *Ars Technica*, and more)

# “The Research Parasite Award” for outstanding secondary data analysis

## 2016

14. Bi W.L., Horowitz P., Greenwald N., Abedalthagafi M., Agarwalla P.K., Gibson W.J., Mei Y., Schumacher S.E., **Ben-David U.**, Chevalier A., Carter S.L., Tiao G., Brastianos P.K., Ligon A.H., Ducar M., MacConaill L.E., Laws E.R., Santagata S., Beroukhim R., Dunn IF. Landscape of genomic alterations in pituitary adenomas. *Clinical Cancer Research*, 2016, 23(7):1841-1851, doi: 10.1158/1078-0432.CCR-16-0790. **IF=12.5**

15. Aguirre A., Meyers R., Weir B., Vazquez F., Zhang C.Z., **Ben-David U.**, Cook A., Ha G., Harrington W., Doshi M., Gill S., Xu H., Ali L., Jiang G., Pantel S., Lee Y., Goodale A., Cherniack A., Oh C., Kryukov G., Cowley G., Garraway L., Stegmaier K., Roberts C., Golub T.R., Meyerson M., Root D., Tsherniak A., and Hahn W. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. *Cancer Discovery*, 2016, 6(8):914-29, doi: 10.1158/2159-8290.CD-16-0154. **IF=39.4**

16. **Ben-David U.**, Ha G., Khadka P., Jin X., Wong B., Franke L. and Golub T.R. The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. *Nature Communications*, 2016, 7:12160, doi:10.1038/ncomms12160. **IF=14.9**

17. Lamm N., **Ben-David U.**, Kerem B. and Benvenisty N. Genomic instability in human pluripotent stem cells arises from replicative stress and chromosome condensation defects. *Cell Stem Cell*, 2016, 18(2): 253-61, doi: 10.1016/j.stem.2015.11.003. **IF=24.6**

## 2015

18. **Ben-David U.**, Cowell Ian G., Austin Caroline C. and Benvenisty N. Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha. *Stem Cells*, 2015, 33(3): 1013-9, doi: 10.1002/stem.1888. **IF=6.3**

# Highlighted in the journal's website

## 2014

19. Weissbein U., **Ben-David U.** and Benvenisty N. Virtual karyotyping reveals greater chromosomal stability in neural cells derived by transdifferentiation than those from stem cells. *Cell Stem Cell*, 2014, 15(6):687-91, doi: 10.1016/j.stem.2014.10.018. **IF=24.6**

20. **Ben-David U.**, Arad G., Weissbein U., Mandefro B., Maimon A., Narwani K., Clark A.T., Andrews P.W., Benvenisty N., and Biancotti J.C. Aneuploidy induces profound changes in

gene expression, proliferation and tumorigenicity of human pluripotent stem cells. *Nature Communications*, 2014, 5:4825, doi: 10.1038/ncomms5825. **IF=14.9**

21. **Ben-David U.\***, Biran A.\*, Scaffidi P., Boehringer M., Meshorer E. and Benvenisty N. Elimination of undifferentiated cancer cells by pluripotent stem cell inhibitors. *Journal of Molecular Cell Biology*, 2014, 6(3):267-9, doi: 10.1093/jmcb/mju012. **IF=6.2**

22. **Ben-David U.** and Benvenisty N. Chemical ablation of tumor-initiating human pluripotent stem cells. *Nature Protocols*, 2014, 9(3):729-40, doi: 10.1038/nprot.2014.050. **IF=13.5**

## 2013

23. **Ben-David U.**, Nudel N. and Benvenisty N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. *Nature Communications*, 2013, 4:1992, doi:10.1038/ncomms2992. **IF=14.9**

# Highlighted in the journal's website and press release

# Highlighted in "Scientific American", "A Week in Science" and "Lab Times" magazines

# "Article of the month" award, Life Sciences Institute, Hebrew University

24. **Ben-David U.**, Gan Q.F., Golan-Lev T., Arora P., Yanuka O., Oren Y.S., Leikin-Frenkel A., Graf M., Garippa R., Boehringer M., Gromo G. and Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. *Cell Stem Cell*, 2013, 12(2):167-79, doi: 10.1016/j.stem.2012.11.015. **IF=24.6**

# "Research Highlight" in *Nature Chemical Biology*, 2013, 9(3): 139

# "Research Highlight" in *Nature/SciBX*, 2013, 6(5): doi:10.1038/scibx.2013.126

# "Article of the month" award, Life Sciences Institute, Hebrew University

# US granted patent 9,456,998, of May 22, 2013, SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS

25. Lee P., Martin N.T., Nakamura K., Azghadi S., Amiri M., **Ben-David U.**, Perlman S., Gatti R.A., Hu H. and Lowry W.E. SMRT compounds abrogate cellular phenotypes of Ataxia Telangiectasia in neural derivatives of patient specific hiPSCs. *Nature Communications*, 2013, 4:1824, doi:10.1038/ncomms2824. **IF=14.9**

26. **Ben-David U.**, Mayshar Y. and Benvenisty N. Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. *Nature Protocols*, 2013, 8(5): 989-97, doi: 10.1038/nprot.2013.051. **IF=13.5**

# Highlighted in the journal's website

## 2012

27. **Ben-David U.** and Benvenisty N. High prevalence of evolutionarily conserved and species-specific genomic aberrations in mouse pluripotent stem cells. *Stem Cells*, 2012, 30(4):612-22, doi: 10.1002/stem.1057. **IF=6.3**

# Highlighted on the cover of the journal and in its website

# "Article of the month" award, Life Sciences Institute, Hebrew University

## 2011

- 28. Ben-David U.**, Mayshar Y. and Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. *Cell Stem Cell*, 2011, 9(2):97-102, doi: 10.1016/j.stem.2011.06.013. **IF=24.6**

# Highlighted in the Editorial and in a Perspective article published in the same issue  
# “Article of the month” award, Life Sciences Institute, Hebrew University

## 2010

- 29. Mayshar Y.\***, **Ben-David U.\***, Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E. and Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. *Cell Stem Cell*, 2010, 7(4):521-31, doi: 10.1016/j.stem.2010.07.017. **IF=24.6**

# "Research Highlight" in *Nature Reviews Cancer*, 2010, 10(11):742  
# “Research Highlight” in *Nature Methods*, 2010, 7(12): 948-9  
# “Article of the year” award, 2010, Life Sciences Institute, Hebrew University

## SUBMITTED MANUSCRIPTS

Nahmad A.D.\*, Reuveni E.\*, Goldschmidt E.\*, Tenne T., Liberman M., Horovitz-Fried M., Khosravi R., Kobo H., Reinstein E., Madi. A. #, **Ben-David U.** #, and Barzel A. # Frequent aneuploidy in primary human T cells following CRISPR-Cas9 cleavage. *Submitted*. doi.org/10.1101/2021.08.20.457092 (bioRxiv)

Waissengrin B., Zahavi T., Salmon-Divon M., Goldberg A., Wolf I., Rubinek T. Winkler T., Farkash O., Grinshpun A., Zubkov A., Khatib M., Strulov Shachar S., Keren N., Carmi-Levy I., **Ben-David U.**, and Amir Sonnenblick<sup>1,2\*</sup>. The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. *Submitted*.

## REVIEWS & PERSPECTIVES

### 2022

- 30. Eliezer Y. and Ben-David U.#** Double genome, double jeopardy. *Nature*, 2022, doi.org/10.1038/d41586-022-00849-2w. **IF=50.0**

### 2021

- 31. Cohen-Sharir Y. and Ben-David U.#** Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A. *Molecular & Cellular Oncology*, 2021, 8(3):1915075, doi.org/10.1080/23723556.2021.1915075. **IF=1.2**

### 2020

- 32. Rendo V., Enache O. and Ben-David U.#** Adding to the CASeload: Unwarranted Cas9-induced activation of the p53 pathway. *Molecular & Cellular Oncology*, 2020, 7(5):1789419, doi.org/10.1080/23723556.2020.1789419. **IF=1.2**

33. **Ben-David U.**<sup>#</sup> and Amon A. Context is everything: aneuploidy in cancer. *Nature Reviews Genetics*, 2020, 21(1):44-62, doi: 10.1038/s441576-019-0171-x. **IF=53.2**

# Highlighted on the cover of the journal

## 2019

34. **Ben-David U.**<sup>#</sup>, Beroukhim R. and Golub T.R. Genomic evolution of cancer models: perils and opportunities. *Nature Reviews Cancer*, 2019, 19(2):97-109, doi: 10.1038/s41568-018-0095-3. **IF=60.7**.

## 2018

35. Odorico. J., Adams A., Melton D., Greenstein G., Hwa A., Nostro C., Rezania A., Oberholzer J., Pipeleers D., Yang L., Cowan C., Huangfu D., Egli D., **Ben-David U.**, Vallier L., Grey S., Tang Q., Roep B., Ricordi C., Naji A., Orlando G., Anderson D., Poznansky M., Ludwig B., Tomei A., Greiner D., Graham M., Carpenter M., Migliaccio G., D'Amour K., Hering B., Piemonti L., Berney T., Rickels M., Kay T. and Markmann J. Report of the Key Opinion Leaders Meeting on Stem Cell-Derived Beta Cells. *Transplantation*, 2018, 102(8):1223-1229, doi: 10.1097/TP.0000000000002217. **IF=4.9**

## 2017

36. Andrews P.W., **Ben-David U.**, Benvenisty N., Coffey P., Eggan K., Knowles B.B., Nagy A., Pera M., Reubinoff B., Rugg-Gunn P.J., Stacey G.N. Assessing the safety of human pluripotent stem cells (PSCs) and their derivatives for clinical applications. *Stem Cell Reports*, 2017, 9(1):1-4, doi: 10.1016/j.stemcr.2017.05.029. **IF=7.8**

## 2015

37. Heslop A.J., Hammond T.G., Santeramo I., Piella A.T., Hopp I., Zhou J., Baty R., Graziano, E.I., Bernabe P., Shaw D.A., Bunn I., Caron A., Skold P., Andrews P.W., Baxter M., Hay D., Hamdam J., Sethu S., Sharpe M.E., Patel S., Jones D.R., Reinhardt J., Danen E.H.J., **Ben-David U.**, Stacey G., Bjorquist P., Rowe, C., Pellegrini G., Antoine D., Cross M.J., Murray P., Williams D., Kitteringham N.R., Park B.K. and Goldring C.E.P. Understanding the risks of stem cell-based therapeutics. *Stem Cells Translational Medicine*, 2015, 4(4):389-400, doi: 10.5966/sctm.2014-0110. **IF=6.9**

## 2014

38. **Ben-David U.**<sup>#</sup> Genomic instability, driver genes and cell selection: Projections from cancer to stem cells. *Biochim Biophys Acta*, 2014, 1849(4):427-35, doi: 10.1016/j.bbagr.2014.08.005. **IF=4.5**

# Highlighted on the cover of the journal

39. Weissbein U., Benvenisty N. and **Ben-David U.**<sup>#</sup> Genome maintenance in pluripotent stem cells. *Journal of Cell Biology* 2014, 204(2):153-63, doi: 10.1083/jcb.201310135. **IF=10.5**

## 2013

40. **Ben-David U.**<sup>#</sup> Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies? *Molecular and Cellular Therapies*, 2013, 1:3, doi:10.1186/2052-8426-1-3. No IF available.

41. **Ben-David U.**, Nissenbaum J. and Benvenisty N. New balance in pluripotency: reprogramming with lineage specifiers. *Cell*, 2013, 153(5): 939-40, doi: 10.1016/j.cell.2013.04.051. **IF=41.6**

## 2012

42. **Ben-David U.**, Kopper O. and Benvenisty N. Expanding the boundaries of embryonic stem cells. *Cell Stem Cell*, 2012, 10(6):666-77, doi: 10.1016/j.stem.2012.05.003. **IF=24.6**

43. **Ben-David U.** and Benvenisty N. Analyzing the genomic integrity of stem cells. *StemBook*, 2012, doi: 10.3824/stembook.1.50.1, <http://www.stembook.org>. No IF available.

44. **Ben-David U.**, Mayshar Y. and Benvenisty N. Significant acquisition of chromosomal aberrations in human adult mesenchymal stem cells: Response to Sensenb  et al. *Cell Stem Cell*, 2012, 10(1):10-11, doi: 10.1016/j.stem.2011.12.007. **IF=24.6**

## 2011

45. Goldring C.E.P., Duffy P.A., Benvenisty N., Andrews P.W., **Ben-David U.**, Eakins R., French N., Hanley N.A., Kelly L., Kitteringham N.R., Kurth J., Ladenheim D., Laverty H., McBlane J., Narayanan G., Patel S., Reinhardt J, Rossi A., Sharpe M. and Park K. Assessing the safety of stem cell therapeutics. *Cell Stem Cell*, 2011, 8(6):618-28, doi: 10.1016/j.stem.2011.05.012. **IF=24.6**

# The cover and the editorial of the journal were dedicated to this article

46. **Ben-David U.** and Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. *Nature Reviews Cancer*, 2011, 11(4): 268-77, doi: 10.1038/nrc3034. **IF=60.7**

# The cover and the editorial of the journal were dedicated to this article

## 2010

47. **Ben-David U.**, Benvenisty N. and Mayshar Y. Genetic instability in human induced pluripotent stem cells: Classification of causes and possible safeguards. *Cell Cycle*, 2010, 9(23): 4603-4, doi: 10.4161/cc.9.23.14094. **IF=4.5**